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PAntiplatelet Therapy
Platelet Cyclooxygenase Inhibition
by Low-Dose Aspirin Is Not Reflected
Consistently by Platelet Function Assays
Implications for Aspirin “Resistance”
Francesca Santilli, MD,* Bianca Rocca, MD, PHD,† Raimondo De Cristofaro, MD,‡
Stefano Lattanzio, BSC,* Laura Pietrangelo, BSC,* Aida Habib, PHD,§ Caterina Pettinella, PHD,*
Antonio Recchiuti, PHD,* Elisabetta Ferrante, BSC,* Giovanni Ciabattoni, MD,* Giovanni Davì, MD,*
Carlo Patrono, MD†
Chieti and Rome, Italy; and Beirut, Lebanon
Objective This study was conducted to assess the thromboxane (TX) dependence of biochemical and functional indexes
used to monitor the effect of low-dose aspirin.
Background Functional assays of the antiplatelet effects of low-dose aspirin variably reflect the TX-dependent component of
platelet aggregation. Previous studies of aspirin resistance were typically based on a single determination of
platelet aggregation.
Methods We assessed the TXB2 dependence of biochemical and functional indexes, as well as their intersubject and intra-
subject variability during administration of the drug and after its withdrawal in 48 healthy volunteers randomized
to receive aspirin 100 mg daily for 1 to 8 weeks.
Results Serum TXB2 was uniformly suppressed by 99% of baseline. Urinary 11-dehydro-TXB2, arachidonic acid-induced
aggregation, and VerifyNow Aspirin (Accumetrics Inc., San Diego, California) showed stable, incomplete inhibi-
tion (65%, 80%, and 35%, respectively). Adenosine diphosphate- and collagen-induced aggregation was highly
variable and poorly affected by aspirin, with an apparent time-dependent reversal. Inhibition of platelet cyclooxy-
genase activity was nonlinearly related to inhibition of platelet aggregation. Platelet function largely recovered
by day 3 post-aspirin, independently of treatment duration. With any functional assay, occasionally “resistant”
subjects were found to be “responders” on previous or subsequent determinations.
Conclusions Platelet cyclooxygenase activity, as reflected by serum TXB2 levels, is uniformly and persistently suppressed by
low-dose aspirin in healthy subjects. However, the effect of aspirin is variably detected by functional assays, po-
tentially leading to misclassification of “responder” as “resistant” phenotypes owing to poor reproducibility of
functional measurements. The nonlinearity of the relationship between inhibition of TX production and inhibition
of platelet function has important clinical implications. (J Am Coll Cardiol 2009;53:667–77) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.047t
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cow-dose aspirin can prevent up to 25% of fatal and
onfatal vascular events in high-risk patients (1,2). Patients
ay experience recurrent events while on aspirin because of
rom the *Center of Excellence on Aging, “G. d’Annunzio” University Foundation,
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eirut, Lebanon. Supported by the European Commission FP6 funding (LSHM-
T-2004-005033). Dr. Davì has received research grant support from Bayer,
anofi-Aventis, and Servier. Dr. Patrono has received research grants from Bayer and
ervier and lecture and consulting fees from AstraZeneca, Bayer, Eli-Lilly, Schering-
lough, Sanofi-Aventis, and Servier. Dr. Rocca has received honoraria from Nycomed
nd Bristol-Myers Squibb. Drs. Santilli and Rocca contributed equally to this work.1
Manuscript received July 25, 2008; revised manuscript received October 8, 2008,
ccepted October 14, 2008.he multifactorial nature of atherothrombosis (3). Such a
reatment failure is often inappropriately referred to as
spirin “resistance” (4). This term has been used also to
ndicate incomplete inhibition of platelet function by low-
ose aspirin, with widely variable estimates of its incidence
nd inconclusive data on its clinical significance (4).
See page 678
Low-dose aspirin inhibits thromboxane (TX)-dependent
latelet function through permanent inactivation of the
yclooxygenase (COX) activity of prostaglandin H synthase(also referred to as COX-1) (2). This represents the
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Aspirin, COX-1 Inhibition, and Platelet Function February 24, 2009:667–77best-characterized mechanism of
action, which fully accounts for the
unique pharmacodynamics of as-
pirin as an antiplatelet agent and
adequately explains the saturability
of its cardioprotective effects at low
doses (1,2). It is already well
known that the various methods
used to quantitate the antiplatelet
effect of aspirin variably reflect the
aspirin-sensitive TX-dependent
component of platelet aggregation
(3). Moreover, different platelet
function tests correlate poorly
among themselves (5). However,
hether the relative contributions of TX-dependent and
independent pathways are constant for any given assay is
argely unknown. This is particularly relevant to the current
ebate on aspirin “resistance” because characterization of
resistant” versus “responder” status is typically based on a
ingle determination of platelet function, with the underly-
ng assumption that this determination represents a stable
henotype (6,7).
The present study assessed the TX dependence of
iochemical and functional indexes commonly used to
onitor the antiplatelet effect of low-dose aspirin, as well
s their intersubject and intrasubject variability during
dministration of the drug and after its withdrawal, in
ealthy volunteers. Moreover, we tested whether the
ntiplatelet response to low-dose aspirin may vary as a
unction of time because of accelerated thrombocytopoi-
sis (8), expression of COX-2 in newly formed platelets
9), or partial recovery of COX-1 activity (10).
ethods
esign of the study. We enrolled 48 healthy Caucasian
ubjects (25 women and 23 men; age range 19 to 38 years,
ean 26.2  4.5 years). Exclusion criteria were athero-
hrombotic disease, bleeding history, gastroduodenal ulcer,
spirin intolerance, obesity, diabetes, cigarette smoking,
yslipidemia, hypertension, and pregnancy. Subjects were
andomized to 1 of 8 groups, according to treatment
uration, ranging from 1 to 8 weeks. Each participant
eceived enteric-coated aspirin (Cardioaspirina, Bayer, Mi-
an, Italy) 100 mg once daily and was instructed to take
ablets at the same time of the day. None of the participants
ad taken vitamin supplements, aspirin, nonsteroidal anti-
nflammatory drugs (NSAIDs), or other antiplatelet drugs
n the preceding 10 days. NSAIDs were not allowed during
he study.
Blood and urine samples were collected after an overnight
ast before starting aspirin (baseline), at the end of each
eek on aspirin, and at days 1, 2, 3, and 7 after withdrawal.
spirin was provided at each visit for the subsequent week.
Abbreviations
and Acronyms
AA  arachidonic acid
ADP  adenosine
diphosphate
COX  cyclooxygenase
CV  coefficient of
variation
NSAID  nonsteroidal
anti-inflammatory drug
Tmax  maximal
aggregation
TX  thromboxaneompliance was measured by pill count. The protocol was (pproved by the Ethics Committee, and written informed
onsent was obtained from each participant.
X-related measurements. One milliliter of blood with-
ut anticoagulant was transferred into a glass tube, incu-
ated for 1 hour at 37°C, and centrifuged at 1,200 g for 10
in. The supernatant serum was stored at 20°C until
ssayed for TXB2 (11). Urinary 11-dehydro-TXB2 was
easured by a previously validated radioimmunoassay (12).
latelet function assays. Optical aggregation was mea-
ured in platelet-rich plasma obtained from citrated blood
0.105 M) using a dual-channel aggregometer (Chrono-
og 490, Chrono-Log, Havertown, Pennsylvania) and
timulated by 1 mM arachidonic acid (AA) (Cayman
hemical Company, Ann Arbor, Michigan), 10 g/ml
ollagen (Mascia Brunelli, Milan, Italy), or 10 M adeno-
ine diphosphate (ADP) (Mascia Brunelli). These agonists
nd their concentrations were chosen based on previous
spirin “resistance” studies (4,13). Maximal aggregation
Tmax) was expressed as % of maximal light transmittance.
VerifyNow Aspirin, kindly provided by Dr. Robert Hill-
an (Accumetrics Inc., San Diego, California), was used on
itrated whole blood, and aggregation was expressed as
spirin response units, as specified by the manufacturer.
latelet COX-2, reticulated platelets, and thrombopoi-
tin measurements. COX-2 expression was assessed by
mmunocytochemistry (9) using anti–COX-2 polyclonal
ntibodies (9) and by flow cytometry on washed and
ermeabilized platelets (9,14) using anti-CD61 and anti–
OX-2 fluorescein-conjugated monoclonal antibodies
Cayman Chemical Company). Reticulated platelets were
easured by the thiazole-orange technique (9). Plasma
hrombopoietin was measured using a commercial kit
R&D Systems, Minneapolis, Minnesota).
tatistical analyses. Data were analyzed by parametric or
onparametric methods according to their distribution. Com-
arisons were made using analysis of variance or the Kruskal-
allis test. Correlations were assessed by the Pearson or
pearman rank test. Differences between baseline and on-
reatment values were analyzed with the t test or Wilcoxon
igned-rank test. Comparisons of time-course curves after
spirin withdrawal were analyzed by 2-factor repeated mea-
urements analysis of variance with the post hoc Holm-Sidak
est for pairwise comparisons (p  0.05). An unpaired t test
as performed to compare measurements of serum TXB2 or
rinary 11-dehydro-TXB2, below or above response thresholds
efined for platelet functional assays. Data are reported as
ean  SD. Significance was defined as p  0.05. All tests
ere 2-tailed; analyses were performed using SPSS (version
3.0, SSPS Inc., Chicago, Illinois) and SigmaStat 3.1 (Systat
oftware Inc., Hounslow, United Kingdom). The intrasubject
oefficient of variation (CV) was the ratio of the SD to the
ean value of each variable in 1 subject at all time points
uring treatment. Corrections for correlated observations
ithin subjects were not made.
Experimental data were fitted using Grafit softwareErithacus Software, Staines, United Kingdom). Different
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February 24, 2009:667–77 Aspirin, COX-1 Inhibition, and Platelet Functionquations were used, and the F test indicated the best fitting
quation. Data of post-aspirin recoveries were analyzed by a
rst-order rate equation:
RtRmax 1 expk tOff [1]
n which R(t) is the percent recovery at time t, Rmax is the
aximum recovery (percentage), k is the first-order rate
Figure 1 Platelet Biochemistry and Function Assay Values Befo
Maximal aggregation (Tmax) values of adenosine diphosphate (ADP)- (A), collagen-
Aspirin (D); and absolute values of serum thromboxane B2 (E) and urinary 11-deh
of baseline (week 0, n  48), week 1 (n  47), week 2 (n  42), week 3 (n  34onstant, and Off is the percentage value of the considered
arameter at day  0.
However, Equation 1 could not properly describe serum
XB2 recovery, and the following equation was used:
RtRmax 1 expk tTs [2]
n which R(t) is the recovery at time t, Rmax is the maximum
d During Aspirin Intake
nd arachidonic acid- (C) induced aggregation; aspirin response units of VerifyNow
romboxane B2 (F) at baseline and during aspirin intake. Values are mean  SD
k 4 (n  28), week 5 (n  23), week 6 (n  17), week 7 (n  11), and week 8re an
(B), a
ydro-th
), wee
(n  6). *p  0.01 versus baseline. #p  0.001 versus baseline.
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Aspirin, COX-1 Inhibition, and Platelet Function February 24, 2009:667–77ecovery, k is the rate constant, and Ts is the time corre-
ponding to the maximum rate of recovery.
The percent inhibition of serum TXB2 was analyzed as a
unction of the corresponding inhibition of other assays.
he shape of the plot showed a complex exponential, rather
han linear, relationship, with an initial linear and subse-
uent steep exponential dependence. Thus, data were ana-
yzed using the following equation.
% inhib a% inhib TXB2 b exp% inhib TXB2
[3]
n which a is the slope of the linear part of the curve and b
s the base of the exponential part of the fit.
esults
he 8 groups were comparable for all baseline measure-
ents (data not shown). The mean interval between aspirin
ntake and blood sampling was 14  4 h (n  47), without
ifferences among groups. One subject dropped out on day
for an unrelated cause, and 1 subject could not be
valuated at weeks 1, 2, and 6, 1 at weeks 4 and 5, and 1 at
eek 7 during the study. Full compliance was recorded by
ill counting.
ADP-induced aggregation was significantly reduced by
spirin (40% maximal inhibition by week 3) but displayed
ubstantial interindividual variability (Fig. 1A). It also
howed time-dependent recovery, with Tmax values at weeks
and 8 comparable to those at baseline (Fig. 1A). However,
hereas baseline platelet aggregation was irreversible, aggrega-
ion at weeks 7 and 8 was consistently reversible (Figs. 1 and 2).
urthermore, light transmittance values of the aggregomet-
ic tracings recorded at 6 min showed similar results and
rends compared with Tmax values (data not shown). Tmax
nd 6-min light transmittance values were positively corre-
ated (r  0.72; p  0.00001). The intrasubject CV of
ercent inhibition of Tmax on aspirin was 70  71%
n  47; range 7% to 320%).
Tmax values of collagen-induced aggregation showed
pproximately 50% inhibition by week 3 of treatment (Fig.
B), with wide interindividual variability. The intrasubject
V of percent inhibition was 47 44% (n 47; range 25%
o 249%).
AA-induced aggregation showed stable inhibition over
he 8-week treatment, averaging 80% (range 50% to 97%)
Fig. 1C). The intrasubject CV of percent of inhibition was
8  9% (n  47; range 1% to 41%).
The VerifyNow Aspirin assay showed a steady 30% to
5% inhibition over the 8-week treatment (Fig. 1D). The
ntrasubject CV of percent inhibition was 19  18% (n 
7; range 2% to 55%).
Serum TXB2 was steadily suppressed over 8 weeks (Fig.
E), absolute values being consistently 10 ng/ml (maxi-
um 8.7 ng/ml). The average percent inhibition wasonstantly above 99%, without significant intergroup differ- dnces: 1-week treatment caused 99.3  0.7% (range 96.3%
o 99.9%) inhibition, and 8-week treatment produced
9.6  0.3% (range 99% to 99.9%) inhibition. The intra-
ubject CV of percent inhibition was 0.3  0.1% (n  47;
ange 0.02% to 2%).
Levels of urinary 11-dehydro-TXB2 were similarly re-
Figure 2
Optical Aggregation Tracings
of Adenosine Diphosphate-Induced Aggregation
From 1 Subject Treated With Aspirin for 8 Weeks
(A) Baseline. (B) 4 weeks on aspirin. (C) 8 weeks on aspirin.uced in the 8 groups (Fig. 1F): 1-week aspirin caused 66
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February 24, 2009:667–77 Aspirin, COX-1 Inhibition, and Platelet Function8% (range 46% to 93%) reduction, and 8-week treatment
esulted in 61  14% (range 42% to 74%) reduction. The
ntrasubject CV of percent inhibition was 21  11% (n 
7; range 10% to 54%). No statistically significant sex-
elated differences were observed during aspirin intake for
ny of the assays (data not shown).
Figure 3 Recovery of Platelet Biochemistry and Function Upon
Panels A and B depict recovery of arachidonic acid-induced aggregation and the V
and D depict recovery of serum thromboxane B2. The plots display data pooled fro
period (C) and detail of recovery over the initial 3 days post-aspirin (D). Panels E
pooled from 1 and 2 weeks versus 3 to 8 weeks of treatment (E) and detail of recRecovery of platelet function by optical aggregation
nd VerifyNow Aspirin followed first-order kinetics and
eached approximately 70% of the relative function at day
post-aspirin, without significant differences between 1
eek and 8 weeks of treatment (Figs 3A and 3B, and data
ot shown).
rin Withdrawal
w Aspirin assay, respectively, following 1 and 8 weeks of treatment. Panels C
nd 2 weeks versus 3 to 8 weeks of treatment for the whole post-treatment
describe recovery of urinary 11-dehydro-thromboxane B2. The plots show data
over the initial 3 days post-aspirin (F). Values are % of baseline and representAspi
erifyNo
m 1 a
and F
overy
mean  SD. The best-fitting curves of the data are shown in each plot. *p  0.01 versus weeks 1 and 2 data.
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Aspirin, COX-1 Inhibition, and Platelet Function February 24, 2009:667–77In contrast, initial recovery of serum TXB2 levels differed
mong groups. At days 1 and 2 following aspirin with-
rawal, TXB2 values were similar in the subjects treated for
and 2 weeks and significantly higher than the correspond-
ng values of longer treatment groups (3 to 8 weeks).
Figure 4 Correlations Between Biochemical and Functional Ass
Individual % inhibition values are depicted from all on-treatment and post-treatmen
11-dehydro-thromboxane B2 and arachidonic acid-induced aggregation (A) and the
serum thromboxane B and arachidonic acid-induced aggregation, VerifyNow Aspiri2xposure to aspirin for at least 3 weeks showed a 2-day
elay before detectable recovery (Fig. 3C). The overall
inetics of TXB2 recovery showed a complex sigmoidal
attern, not appropriately described by the first-order kinet-
cs of the other assays (Fig. 3), confirmed by F testing (p 
surements. Linear relationships are shown between inhibition of urinary
ow Aspirin assay (B). (C to E) Nonlinear relationships between inhibition of
urinary 11-dehydro-thromboxane B . (F) Detail of panel E.ays
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February 24, 2009:667–77 Aspirin, COX-1 Inhibition, and Platelet Function.001 vs. first-order fitting). Whereas the values obtained
ith platelet functional assays had largely recovered by day
post-aspirin (Figs. 3A and 3B), day 3 TXB2 values still
veraged 45% of baseline (Figs. 3C and 3D); full recovery
ccurred by day 7 post-aspirin (Fig. 3C).
Recovery of 11-dehydro-TXB2 displayed first-order ki-
etics (Fig. 3E). Subjects treated for 1 and 2 weeks showed
ignificantly faster recovery compared with the other sub-
ects (Fig. 3F).
Correlations between percent inhibition of the different
ssays included measurements during and post-aspirin,
hich allowed the investigation of these relationships over a
roader range of values. Platelet aggregation, VerifyNow
spirin, and urinary 11-dehydro-TXB2 were all linearly
orrelated, the highest coefficients being observed among
A-induced aggregation, VerifyNow Aspirin, and 11-
ehydro-TXB2 (Figs. 4A and 4B, Table 1). However, a
inear model could not properly describe the correlation
etween percent inhibition of serum TXB2 and other assays,
hich displayed a complex relationship. This relationship
howed an initial linear and subsequent steep exponential
ependence (F testing: p  0.001 vs. linear fitting) (Figs.
C to 4F). The nonlinear relationship between percent
nhibition of serum TXB2 and urinary 11-dehydro-TXB2
howed that for 0 to 97% of COX inhibition, TX biosyn-
hesis in vivo was linearly inhibited by 40% and that
97% suppression of serum TXB2 was necessary to maxi-
ally reduce TX metabolite excretion (Figs. 4E and 4F).
We next investigated whether serum TXB2 and urinary
1-dehydro-TXB2 levels differed in association with func-
ional measurements defined as “responder” or “resistant,”
sing arbitrary thresholds, as described in previous studies
4,13). No statistically significant differences in TX-related
ndexes were observed between measurements below or above
hese thresholds (Fig. 5). Furthermore, with any assay, occa-
ionally “resistant” subjects were found to be “responders” on
revious or subsequent determinations (Fig. 6).
Aspirin did not modify plasma thrombopoietin levels,
eripheral platelet counts, mean platelet volume, or platelet
istribution width (Fig. 7A and data not shown). During 8
eeks of aspirin exposure, the percentage of reticulated
latelets, the youngest and mRNA-richest platelets (15),
as not modified (Fig. 7B). Similarly, the fraction of
latelets expressing COX-2 was not altered by aspirin (Figs.
orrelations Among Absolute Values and Percentage Inhibition Val
Table 1 Correlations Among Absolute Values and Percentage I
VerifyNow
Aspirin
A
A
VerifyNow Aspirin —
ADP-induced aggregation 0.36 (0.20)
Collagen-induced aggregation 0.60 (0.46)
11-dehydro-TXB2 0.69 (0.70)
AA-induced aggregation 0.75 (0.68)
alues in parentheses indicate the correlations among percentage inhibition values. All correlatio
AA  arachidonic acid; ADP  adenosine diphosphate; TX  thromboxane.C to 7E). piscussion
lthough initial evaluation of aspirin as an antithrombotic
gent was based on functional assays predicting the require-
ent of relatively high doses and 3 or 4 times daily dosing
egimens (16), further development of low-dose aspirin was
argely based on biochemical assays reflecting its mechanism
f action (17–19). The latter successfully predicted 2 novel
eatures of the drug, that is, an optimal once-daily regimen
nd saturability of the antithrombotic effect at low doses.
nterest in optical platelet aggregation was resurrected by
he first description of so-called aspirin “resistance” in 1994
20). Based on more than 500 publications on the topic (4),
t has been proposed that aspirin “resistance” represents a
rue clinical diagnosis, requiring a change in antiplatelet
herapy (21). Intrinsic to this suggestion is the underlying
ssumption that a single determination of agonist-induced
latelet aggregation can determine whether aspirin has fully
nhibited platelet COX activity and can define a stable
resistant” or “nonresponder” phenotype based on arbitrary
hresholds of functional response (4,6,13).
We compared different functional and biochemical assays
or their capacities to detect the antiplatelet effect of aspirin,
00 mg given orally for 1 to 8 weeks to 48 healthy subjects.
ovel aspects of the study design included up to 8 repeated
easurements in the same subjects to assess reproducibility
f the various assays, as well as analysis of the recovery
ollowing withdrawal. The latter allowed characterization of
spirin’s kinetics and also provided data on a wide range of
nhibitory values of platelet COX activity to fully describe
he relationship between inhibition of enzyme activity and
nhibition of TX-dependent platelet function.
We found that platelet COX activity, as reflected by
erum TXB2 values (11,22), and TX-dependent platelet
unction, as reflected by AA-induced platelet aggregation
nd VerifyNow Aspirin values, were uniformly suppressed
uring prolonged exposure to aspirin, encompassing up to 5
o 6 platelet regeneration cycles and well beyond the
teady-state of its pharmacodynamic effect at 100 mg daily
22). We found no evidence of time-dependent changes in
everal indexes of thrombocytopoiesis, including the per-
entage of reticulated or COX-2–expressing platelets, a
henomenon that transiently characterizes newly formed
ith Different Methods
ion Values With Different Methods
uced
ation
Collagen-Induced
Aggregation 11-dehydro-TXB2
— —
— —
.44) — —
.19) 0.56 (0.45) —
.25) 0.63 (0.54) 0.72 (0.63)
tatistically significant (p  0.001).ues W
nhibit
DP-Ind
ggreg
—
—
0.57 (0
0.37 (0
0.40 (0latelets (9,15).
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Aspirin, COX-1 Inhibition, and Platelet Function February 24, 2009:667–77Among the biochemical and functional assays, serum
XB2 had the highest signal-to-noise ratio and the lowest
nterindividual and intraindividual variabilities. Aspirin, al-
hough an effective inhibitor of platelet TX production
11,18,22), is often considered a weak platelet inhibitor
ecause of its limited effects on aggregation by high con-
entrations of ADP or collagen. This may account for some
f the variability of the response to these agonists, which, in
ontrast to AA, activate platelets through both TX-
ependent and -independent pathways (3). The paradoxical
ncrease in light transmittance with persistence of reversible
ggregation, recorded at 7 and 8 weeks on aspirin, might
eflect complex physical properties of the ADP-induced
urbidimetric signal (23,24), rather than a real platelet
ecovery, as indicated by the stable inhibition of TX-
ependent aggregation. However, whether the paradoxical
Figure 5 Platelet Cyclooxygenase Activity and Thromboxane B
Associated With “Responder” Versus “Nonresponder”
Absolute values of serum thromboxane B2 (A) and urinary 11-dehydro-thromboxan
bars) defined thresholds of different functional assays, are depicted as mean  S
the thresholds is indicated above the columns. VerifyNow Aspirin thresholds are re
response to different agonists are indicated as maximal aggregation (Tmax). No sta
metabolite values below and above these thresholds. ADP  adenosine diphosphncrease in Tmax reflects a change in the ratio of small to rarge platelet aggregates or a change in the signaling
athway for the first phase of ADP-induced aggregation
emains to be established.
In contrast to measurements of serum TXB2, for which
very measurement of more than 200 values during aspirin
ntake was suppressed by at least 97% versus baseline,
easurements of various functional indexes categorized
ccording to previously described thresholds (21,25), iden-
ified 1.4% to 30% of “nonresponder” samples. However,
nspection of prior or subsequent determinations performed
n the same subjects clearly identified the fluctuating nature
f this apparent “nonresponder” phenotype, most likely
eflecting the relatively poor intrasubject reproducibility of
unctional measurements (4,26). These findings clearly in-
icate that functional assays cannot predict which individ-
als have effective inhibition of platelet TX production in
thesis
tional Measurements
), associated with all measurements falling below (open bars) or above (solid
number (n) of measurements for each functional assay falling below or above
in aspirin response units (ARU), and the thresholds of optical aggregation in
lly significant differences were found for any comparison between thromboxaneiosyn
Func
e B2 (B
D. The
ported
tistica
ate.esponse to aspirin.
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February 24, 2009:667–77 Aspirin, COX-1 Inhibition, and Platelet FunctionOne major limitation of the present study is that it was
arried out in healthy volunteers. It might be argued that
latelet aggregation patterns may be different in patients
ith vascular disease. However, the practical implications of
he 2 major findings of the present study would still apply to
oth populations. In fact, the variability of the TX-
ndependent component of the different aggregation signals
nd the instability of the “resistant” phenotype are likely to
e amplified, rather than diminished, by cardiovascular
iseases. Therefore, establishing the pattern in a normal
opulation constitutes a sound and necessary basis to
nterpret observations in patients.
Given the requirement for 97% suppression of plate-
et COX activity to maximally inhibit TX-dependent
latelet function, less than adequate suppression caused
y noncompliance or pharmacodynamic interactions with
ome traditional NSAIDs (27,28) is best reflected by
erum TXB2.
Based on the average effects of different doses of aspirin,
p to 2,600 mg daily, and a selective TX synthase inhibitor,
eilly and FitzGerald (29) previously described the strik-
Figure 6 Inconsistency of the “Resistant” Status of Individual
Repeated measurements of arachidonic acid-induced aggregation (A), VerifyNow A
aggregation (D) are represented, with each symbol and line depicting 1 of 3 subje
cates a commonly used threshold for “resistance.” Tmax  maximal aggregation.ngly nonlinear relationship between inhibition of serum sXB2 ex vivo and inhibition of TX biosynthesis in vivo and
redicted that virtually complete suppression of the biosyn-
hetic capacity of platelets is required to have a measurable
mpact on TX-dependent platelet function. Our detailed
nalysis of such a relationship provides direct evidence and
inetic interpretation for this hypothesis.
Inhibition of platelet COX activity, explored both on and
ff treatment, was nonlinearly related to inhibition of
X-dependent platelet function, leading to faster functional
ecovery following aspirin withdrawal than predicted by the
ate of platelet turnover. Thus, 3 days after stopping aspirin,
A-induced platelet aggregation and VerifyNow Aspirin
ad recovered approximately 60% and 80% of baseline
alues, respectively. This finding may have clinical implica-
ions for the adequacy of recommended timing of drug
ithdrawal before surgical/invasive procedures in aspirin-
reated patients (30,31). The nonlinearity of the relationship
etween inhibition of the TX biosynthetic capacity and
nhibition of TX-dependent platelet function enables some
ecovery of platelet function at 48 hours after drug with-
rawal, a phenomenon that may be substantial in some
cts Treated With Low-Dose Aspirin
(B), adenosine diphosphate (ADP)-induced aggregation (C), and collagen-induced
ated with aspirin for 3 to 8 weeks. The horizontal dotted line in each panel indi-Subje
spirin
cts treubjects because of the interindividual variability in platelet
t
e
t
W
s
c
C
b
p
n
b
o
t
r
w
A
T
676 Santilli et al. JACC Vol. 53, No. 8, 2009
Aspirin, COX-1 Inhibition, and Platelet Function February 24, 2009:667–77urnover. This may have contributed to the less than
xpected reduction in vascular complications associated with
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omen’s Health Study (32). Additional studies in clinical
ettings characterized by enhanced platelet turnover are
learly warranted.
We conclude that in healthy subjects: 1) platelet
OX-1 activity is uniformly and persistently suppressed
y low-dose aspirin; 2) this effect is variably detected by
Figure 7 Effects of Low-Dose Aspirin on Thrombocytopoietic In
(A) Thrombopoietin levels in the 8 groups at baseline (open bars) and on the last
of 6 subjects treated for 8 weeks with aspirin at baseline and at the end of the tr
gated on platelets (CD61 positive) before and at the end of 8 weeks of aspirin in
baseline (D) and after 8 weeks of aspirin (E). *COX-2–positive platelets (dark brolatelet function assays, potentially leading to the erro- aeous diagnosis of aspirin “resistance,” particularly when
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f the relationship between inhibition of TXA2 produc-
ion and inhibition of platelet function allows rapid
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